Abstract 3982
Background
A special role in the tumour progression is played by heterogeneous components of the microenvironment of tumours, premetastatic tumour niches, influencing which seems likely to change the disease course. Our purpose was to analyze some characteristics of the local cellular immunity in metastatic GC.
Methods
33 GC patients aged 30-80 years were divided into 2 groups: group 1 – M0, non-metastatic GC, n = 17, mean age 61.7±8.9 years (G2 – 11, G3 – 6 patients); group 2 – M1, GC with peritoneal and omentum metastases, n = 16, mean age 58.7±11.5 years (G2 – 7, G3 – 5, G4 - 3 patients). Tumours (T), peritumoral tissues (PT), omentum (O) and peritoneum (P) tissues were studied. Lymphocytes were determined by flow cytometry using FACSCantoII (BD) and T-, B-, NK antibody panels; quantitative content of DN (CD3+CD4-CD8-), DP (CD3+CD4+CD8+) T lymphocytes and regulatory (T-regs) T cells (CD4+CD25+CD127dim) was studied.
Results
Patients with M1 GC demonstrated increased CD3+ lymphocytic infiltration of T, PT, O and P tissues. IRI in M1 O was significantly higher than in M0 (1.95±0.3 vs 0.7±0.2), being similar in other tissues. Levels of DN lymphocytes were lower in O of M1, compared to M0 (7.7±2.5 vs 15.7±5.6, p ≤ 0.05). Contents of NK cells, NKT lymphocytes significantly decreased in O of M1 patients, compared to M0 (3.3≤1.1 vs 14.0≤2.3 and 1.7±0.5 vs 3.8±0.8, respectively). Higher levels of NKT lymphocytes were registered in M1 PT, compared to M0 (3.3±1.1 vs 1.3±0.4), as well as lower levels of NK cells in T (2.3±0.9 vs 5.33±0.2). Percentage of Treg lymphocytes in P and O were significantly lower in M1 than in M0 (respectively, 6.9±1.5 vs 12.6±4.9 and 5.9±1.3 vs 12.6±4.9). Higher amount of B lymphocytes was registered in all tissues of M1 patients, compared to M0, maximal in O (13.1±3.3 vs 3.4±1.5), T (23.5±5.1 vs 17.2±2.3) and P (8.2±3.4 vs 3.5±1.2), while in PT it was lower (15.7±4.2 vs 43.7±4.5).
Conclusions
GC metastasis to the omentum and peritoneum is characterized by a change in their immunological features – a decrease in the tissue level of NK and NKT lymphocytes, a loss in the prevalence of CD3+CD8+ due to an increase in the number of CD3+CD4+ cells, and an increase in the level of CD19 + (B2) lymphocytes. This probably contributes to the appearance of metastatic lesions in these organs in gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract
5812 - Correlation between the density of tumor-infiltrating lymphocytes, immune cell subsets in tumor stroma and response to systemic therapy in breast cancer
Presenter: Cvetka Grasic Kuhar
Session: Poster Display session 2
Resources:
Abstract
4734 - BRCA1/2 Testing in HER2- Advanced Breast Cancer (ABC): Results from the European Component of a Multi-Country Real World Study
Presenter: Michael Patrick Lux
Session: Poster Display session 2
Resources:
Abstract
1686 - In vitro and in vivo rescue of resistance to BET inhibitors by targeting PLK1 in triple negative breast cancer.
Presenter: Cristina Nieto-jiménez
Session: Poster Display session 2
Resources:
Abstract
5020 - Neoadjuvant endocrine therapy in combination with melatonin and metformin in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
5082 - Melatonin and metformin in neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Tatiana Semiglazova
Session: Poster Display session 2
Resources:
Abstract
2642 - Patient-tailored tamoxifen dosing based on an increased quantitative understanding of its complex pharmacokinetics: A novel integrative modelling approach
Presenter: Anna Mueller-Schoell
Session: Poster Display session 2
Resources:
Abstract
2461 - Lack of benefit of neoadjuvant pertuzumab in high risk HER2 positive breast cancer. A retrospective case-control study of 355 cases with biomarker analysis.
Presenter: Manuela Tiako Meyo
Session: Poster Display session 2
Resources:
Abstract
4776 - Targeting CDCA3 to improve chemotherapy response in triple-negative breast cancer patients
Presenter: Kenneth O'Byrne
Session: Poster Display session 2
Resources:
Abstract
1674 - Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Presenter: María Del Mar Noblejas López
Session: Poster Display session 2
Resources:
Abstract